Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KXV01 TCR Lentinvivo in Advanced Solid Tumors
NCT07275853Phase 1Recruiting
- Sponsor
- TScan Therapeutics, Inc.
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KXV01 TCR Lentinvivo in solid tumor, sponsored by TScan Therapeutics, Inc. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
KXV01 TCR Lentinvivo
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07275853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275853.